Healthcare Equipment and Supplies
Company Overview of CardioDx, Inc.
CardioDx, Inc. operates a molecular diagnostics company that develops and commercializes proprietary tests to help improve treatment decisions, enhance patient outcomes, and reduce the overall cost of care. The company’s initial focus is on diagnostics for cardiovascular diseases, specifically coronary artery disease (CAD), arrhythmia, and heart failure. Its solution includes Corus CAD test, which is a commercially available blood-based gene expression test that provides an assessment for non-diabetic patients with symptoms that are suggestive of obstructive CAD. The company markets its Corus CAD test to healthcare providers through its direct sales force in the United States. CardioDx, Inc....
600 Saginaw Drive
Redwood City, CA 94063
Founded in 2003
Key Executives for CardioDx, Inc.
Vice President of Operations
Compensation as of Fiscal Year 2014.
CardioDx, Inc. Key Developments
CardioDx Announces New Leadership Appointments
Apr 28 14
CardioDx, Inc. announced that diagnostics industry veterans Melinda Griffith, J.D., and Doug Ross, M.D., Ph.D., have joined the executive team as Head of Corporate Development and General Counsel, and Chief Scientific Officer, respectively. In addition, the company has announced the appointment of James Tobin and Andrew Guggenhime to the Board of Directors. Andrew Guggenhime will be transitioning from his role as Chief Financial Officer of CardioDx to this new position. Prior to joining CardioDx, Ms. Griffith served in multiple executive management positions at Clarient, Inc. Most recently, Dr. Ross was an independent consultant serving as Acting Chief Scientific Officer of the Medical Science division of Life Technologies Corporation, helping guide research and development as well as strategic partnerships initiatives. With more than 40 years of healthcare industry experience, Mr. Tobin previously served as CEO and President of Boston Scientific Corporation. Mr. Guggenhime brings strong leadership, management, business, and financial expertise from the life sciences sector to the CardioDx Board of Directors. Mr. Guggenhime joined CardioDx as Chief Financial Officer in September 2011.
CardioDx, Inc. Auditor Raises 'Going Concern' Doubt
Apr 28 14
CardioDx, Inc. filed its S-1/A on Apr 28, 2014 for the period ending Dec 31, 2013. In this report its auditor, Ernst & Young LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
CardioDx, Inc. and Medison Enter into an Exclusive Corus Cad Product Marketing and Sales Agreement
Apr 9 14
CardioDx, Inc. and Medison announced that they have entered into an agreement granting Medison Israel the exclusive right to market and sell CardioDx's Corus(R) CAD blood-based genomic diagnostic test for the assessment of obstructive coronary artery disease (CAD) in Israel. Corus CAD is the first and only commercially available gene expression test that provides a current-state assessment of obstructive CAD in non-diabetic patients presenting with typical or atypical symptoms. It is the only sex-specific test for the diagnosis of obstructive CAD that accounts for critical biological differences between men and women. Corus CAD helps clinicians more accurately determine early in the diagnostic work-up whether or not their patient's symptoms are due to obstructive CAD. Under the agreement, Medison will make Corus CAD available to patients in Israel, where heart disease is the second leading cause of mortality and is responsible for approximately 16% of all deaths each year. Blood samples collected from patients in Israel for Corus CAD testing will be sent to CardioDx's CLIA-certified laboratory in Palo Alto, California, for rapid analysis and test reporting. Based in Petach Tikva, Medison delivers innovative healthcare solutions in the areas of cardiology, human genetics, neurology, oncology, gastroenterology, nephrology, hematology, endocrinology, infectious diseases, and allergology. With its long-standing relationships with health maintenance organizations, medical centers, and physicians, Medison is working with physicians within Israel to provide individualized treatments for their patients. The company has been active within the cardiology field for more than a decade and has extensive experience in obstructive CAD.
Similar Private Companies By Industry
Recent Private Companies Transactions
July 19, 2014